Renalytix Plc (RNLXY)
OTCMKTS · Delayed Price · Currency is USD
0.2700
0.00 (0.00%)
Oct 2, 2025, 4:00 PM EDT
Renalytix Revenue
Renalytix had revenue of $1.25M in the quarter ending December 31, 2024, with 76.45% growth. This brings the company's revenue in the last twelve months to $2.89M, up 20.08% year-over-year. In the fiscal year ending June 30, 2024, Renalytix had annual revenue of $2.29M, down -32.74%.
Revenue (ttm)
2.89M
Revenue Growth
+20.08%
P/S Ratio
14.20
Revenue / Employee
n/a
Employees
n/a
Market Cap
41.10M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 2.29M | -1.11M | -32.74% |
| Jun 30, 2023 | 3.40M | 433.00K | 14.58% |
| Jun 30, 2022 | 2.97M | 1.48M | 99.20% |
| Jun 30, 2021 | 1.49M | - | - |
| Jun 30, 2020 | - | - | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 105.45M |
| Tian'an Technology Group | 2.12M |
| Glass House Brands | 221.55M |
| Northwest Biotherapeutics | 1.09M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| Jushi Holdings | 256.36M |
Renalytix News
- 18 days ago - Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease - PRNewsWire
- 2 months ago - MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities - PRNewsWire
- 7 months ago - Renalytix Plc (RNLXY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 11 months ago - Renalytix plc Reports Financial Results for First Quarter of Fiscal Year 2025 - PRNewsWire